(2) Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY
Transduced cells were selected with 2 g/ml puromycin (Sigma-Aldrich, TR-1003-G).The DNA sequences of these shRNA genes were as follows: sh-NRF2-a forward: 5- CCG GCT TGC ATT AAT TCG GGA TAT ACT CGA GTA TAT CCC GAA TTA ATG CAA GTT TTT G-3 and reverse, 5- AAT TCA AAA ACT TGC ATT AAT TCG GGA TAT ACT CGA GTA TAT CCC GAA TTA ATG CAA G-3, sh-NRF2-b forward: 5-CCG GAG AGC AAG ATT TAG ATC ATT TCT CGA GAA ATG ATC TAA ATC TTG CTC TTT TTT G-3 and reverse, 5- AAT TCA AAA AAG AGC AAG ATT TAG ATC ATT TCT CGA GAA ATG ATC TAA ATC TTG CTC T-3, sh-C forward: 5- CCG GGC AAG CTG ACC CTG AAG TTC ACT CGA GTG AAC TTC AGG GTC AGC TTG CTT TTT G-3 and reverse, 5- AAT TCA AAA AGC AAG CTG ACC CTG AAG TTC ACT CGA GTG AAC TTC AGG GTC AGC TTG C-3
Participants taking a 2.4 mg dose of semaglutide lost an average of nearly 15% of their initial body weight over 68 weeks
Lab monitoring is individualized
Proven non-habit-forming pain management therapies FDA-approved medications delivered to you in discreet packaging Access to board-certified pain management specialists Convenient, online visits Explore Pain Management Treatments